Breaking News, Promotions & Moves

Scenic Biotech Appoints Roland W. Bürli Chief Scientific Officer

Bürli will lead the development and advance the pipeline of modifier therapies in neuro- and metabolic diseases.

By: Rachel Klemovitch

Assistant Editor

Scenic Biotech, a pioneer in modifier therapies for severe diseases, appointed Roland W. Bürli, PhD, as Chief Scientific Officer (CSO), effective September 1, 2025.  At Scenic, Bürli will oversee the company’s scientific strategy and guide the advancement of the pipeline of first-in-class modifier therapies addressing neurodegenerative and metabolic diseases. Bürli brings over 25 years of experience in drug development and has held senior leadership roles across pharmaceutical and biotechn...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters